Is Egrifta (Tesamorelin) Legal in Louisiana?

The Short Answer on Legality

Tesamorelin is a legal prescription medication in Louisiana. The FDA cleared it under NDA 022505 in November 2010, and no Louisiana statute independently schedules or bans it. A licensed prescriber must write the order, and a licensed pharmacy must dispense it. Outside that chain, possession of pharmaceutical-grade tesamorelin without a prescription is not authorized under state or federal law.

Louisiana follows the federal Controlled Substances Act as its baseline scheduling authority. Because the DEA has not placed tesamorelin in any schedule, it is treated as a non-controlled legend drug, meaning a prescription is required but no DEA-level triplicate or special reporting applies beyond standard drug monitoring. The Louisiana Uniform Controlled Dangerous Substances Law (La. R.S. 40:961 et seq.) mirrors federal schedules and adds no extra restrictions on tesamorelin specifically.

FDA Approval: The Foundation of Legal Status

The FDA approved Egrifta (tesamorelin for injection) on November 10, 2010, making it the first growth-hormone-releasing factor analogue cleared for a specific clinical indication in the United States. The approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The approval was based on two Phase 3 randomized controlled trials (LIPO-010A and LIPO-010B, combined N=816), in which tesamorelin 2 mg subcutaneously daily for 26 weeks reduced visceral adipose tissue by a mean of 15.2% versus 1.2% placebo (P<0.001) as measured by CT scan [1].

FDA approval means the drug has an established manufacturing standard, a package insert, and a legal commercial supply chain through Theratechnologies Inc. That status is what makes dispensing in Louisiana straightforward for the on-label indication.

Off-Label Prescribing in Louisiana

Off-label prescribing is legal and common in Louisiana, as in all U.S. States, under the medical practice act. The Louisiana State Board of Medical Examiners does not prohibit off-label use, provided the prescriber documents clinical justification in the medical record and obtains informed patient consent where appropriate. Clinicians in Louisiana have used tesamorelin off-label for age-related growth hormone decline, non-HIV visceral adiposity, and metabolic syndrome, though insurance reimbursement for off-label use is generally not available [2].

A 2012 consensus statement from The Endocrine Society noted that GH secretagogues like tesamorelin "should not be used outside of approved indications without careful documentation of clinical rationale," a standard Louisiana providers are expected to meet [3].

Federal Regulatory Framework Governing Tesamorelin

NDA 022505 and the Legend Drug Classification

Because tesamorelin holds an approved NDA, it is a Schedule II of the Food Drug and Cosmetic Act Section 503(b) legend drug. That means it requires a prescription but is not a controlled substance. Pharmacies in Louisiana can stock and dispense branded Egrifta through normal wholesale channels without DEA vault storage or quantity limits beyond standard pharmacy law [4].

The FDA's Orange Book lists Egrifta as having no generic equivalents as of early 2025, meaning compounded versions cannot rely on a "pharmaceutical equivalent" pathway. Compounded tesamorelin must instead meet separate criteria under Sections 503A and 503B of the FD&C Act [5].

The 503A Compounding Pathway

Section 503A of the FD&C Act governs traditional compounding pharmacies. Under 503A, a pharmacy may compound a drug that is commercially available if the prescriber documents a specific medical need that the commercial product cannot meet, such as a required alternative dosage form or concentration. Tesamorelin is commercially available as Egrifta (2 mg/vial), so 503A compounding is permitted only when such a documented patient-specific need exists.

The FDA has periodically updated its list of "bulk drug substances that present demonstrable difficulties for compounding" (the so-called 503A bulks list). As of January 2025, tesamorelin has not been placed on the list of substances that may not be compounded under 503A, nor has it been designated a Category 1 (approved for compounding) substance. It exists in a regulatory middle ground: not prohibited, not explicitly cleared, meaning compounding decisions rest on the prescriber's documented rationale and the pharmacy's compliance with USP <797> sterile standards [6].

The 503B Outsourcing Facility Pathway

Section 503B outsourcing facilities can produce tesamorelin in larger batches without patient-specific prescriptions, but must register with the FDA, comply with current Good Manufacturing Practices (cGMP), and follow the 503B bulks list. Tesamorelin is not on the FDA's 503B Category 1 approved bulks list as of early 2025, which means 503B outsourcing facilities do not have explicit FDA authorization to produce it in bulk. Facilities that do so operate in a gray zone and risk FDA enforcement action [7].

Patients in Louisiana should ask any compounding pharmacy whether it is 503A or 503B registered and whether its tesamorelin product has been tested for potency, sterility, and endotoxins per USP <797> and USP <71> standards before dispensing.

FDA Enforcement Posture on Compounded Peptides

The FDA issued a series of warning letters between 2020 and 2024 targeting compounding pharmacies producing unauthorized peptides. While those letters focused heavily on BPC-157 and TB-500 (which are not FDA-approved), the enforcement trend signals increased scrutiny of all compounded peptides. Tesamorelin's NDA approval provides a layer of protection not available to unapproved peptides, but compounders must still satisfy the patient-specific or outsourcing-facility requirements outlined above [8].

Louisiana State Law: What the Board of Pharmacy Actually Says

Louisiana Board of Pharmacy Rules

The Louisiana Board of Pharmacy (LBP) licenses all in-state pharmacies and applies federal compounding standards through its administrative code (LAC 46:LIII). Louisiana pharmacy law requires that compounded sterile preparations meet USP <797> standards, and the LBP conducts inspections to verify compliance [9].

Louisiana does not maintain a separate state-level peptide prohibition list beyond federal scheduling. The LBP has not issued a specific policy statement restricting tesamorelin compounding as of early 2025. A prescriber in Louisiana who writes a tesamorelin prescription for an off-label indication should document the rationale, because if the LBP or a payer audits the prescription, that documentation supports the pharmacist's dispensing decision [10].

Louisiana Medical Practice Act and Prescriber Authority

Under La. R.S. 37:1261 et seq., licensed physicians hold broad authority to prescribe any non-controlled legend drug for any indication they judge to be clinically appropriate. Nurse practitioners and physician assistants with collaborative practice agreements may also prescribe tesamorelin within their scope. The Louisiana State Board of Medical Examiners has not issued any advisory opinion singling out tesamorelin or growth-hormone-related peptides for restriction [11].

A practical three-tier framework for Louisiana prescribers:

1. On-label (HIV lipodystrophy): Write the prescription for branded Egrifta, submit to a standard pharmacy, document the HIV diagnosis and lipodystrophy findings.
2. Off-label (e.g., age-related GH decline, metabolic adiposity without HIV): Document clinical labs (IGF-1, fasting glucose, HbA1c), informed consent, and specific therapeutic goal. Compounded tesamorelin from a 503A-compliant pharmacy is the usual dispensing route because branded Egrifta is rarely covered off-label.
3. Telehealth-initiated: Louisiana telehealth law (La. R.S. 40:1223.3) permits prescribing following a synchronous audio-video encounter. A valid provider-patient relationship must be established before any prescription is issued [12].

How to Get Egrifta (Tesamorelin) in Louisiana

Step 1: Find a Qualified Prescriber

Any Louisiana-licensed MD, DO, NP, or PA with prescriptive authority can write a tesamorelin prescription. Endocrinologists, infectious disease specialists (for HIV lipodystrophy), and hormone therapy-focused clinicians are the most common prescribers. Telehealth platforms, including HealthRX, can connect Louisiana patients with licensed providers via synchronous video visits, satisfying the state's telemedicine prescribing requirements [12].

Step 2: Obtain Baseline Labs

Before prescribing tesamorelin, most clinicians will order:

• IGF-1 (insulin-like growth factor 1) to assess baseline GH axis activity
• Fasting glucose and HbA1c, because tesamorelin can increase glucose levels (a known class effect)
• A lipid panel, given the visceral adiposity context
• An abdominal CT or DXA scan if visceral fat quantification is needed for documentation

In the key LIPO trials, mean IGF-1 increased by 144 mcg/L from baseline in the tesamorelin group versus 5 mcg/L in placebo over 26 weeks, confirming biological activity [1]. Monitoring IGF-1 every 3 to 6 months during therapy is standard practice per Endocrine Society guidelines [3].

Step 3: Choose the Right Pharmacy

For on-label HIV lipodystrophy, specialty pharmacies that handle HIV medications (such as CVS Specialty or Walgreens Specialty) can dispense branded Egrifta. Manufacturer support programs through Theratechnologies may assist with prior authorization.

For off-label use, a 503A-registered compounding pharmacy is the standard route. Louisiana patients should verify that the pharmacy:

• Holds an active Louisiana Board of Pharmacy permit
• Compounds under USP <797> sterile compounding standards
• Provides a certificate of analysis (CoA) from an independent third-party lab confirming potency and sterility [6]

Step 4: Understand Dosing and Administration

The FDA-approved dose of tesamorelin is 2 mg subcutaneously once daily, injected into the abdomen. Off-label protocols used in clinical research have ranged from 1 mg to 2 mg daily. Patients self-administer after training. Reconstitution requires sterile water for injection (supplied with branded Egrifta or provided separately with compounded vials).

A 2012 study published in the Journal of Acquired Immune Deficiency Syndromes (N=273) confirmed that after 52 weeks of continuous use, visceral adipose tissue remained reduced by 18% from baseline compared with 3% in placebo, demonstrating sustained efficacy with ongoing dosing [13]. Discontinuation leads to visceral fat reaccumulation within 12 weeks in most patients, so long-term prescribing decisions should factor in this rebound effect.

Step 5: Insurance and Cost Considerations

Branded Egrifta carries a list price exceeding $4,000 per month. For HIV lipodystrophy, Medicaid in Louisiana (Healthy Louisiana) covers Egrifta with prior authorization under the HIV/AIDS pharmaceutical benefit, though formulary tiers vary by managed care organization [14]. Off-label use is almost never covered by insurance, making compounded tesamorelin (typically $150 to $400 per month from 503A pharmacies) the practical alternative for most patients.

Safety Profile and Monitoring Requirements in Louisiana Clinical Practice

Known Adverse Effects

The FDA label lists the following adverse reactions occurring in more than 5% of Egrifta-treated patients: peripheral edema, arthralgia, pain in extremity, and myalgia. Glucose intolerance is a class effect of GH secretagogues. In the Phase 3 trials, fasting glucose increased by a mean of 4.2 mg/dL in the tesamorelin group versus a 1.0 mg/dL decrease in placebo over 26 weeks [1].

Tesamorelin is contraindicated in active malignancy, pregnancy, and hypersensitivity to tesamorelin or mannitol. The FDA label also warns against use in patients with disruption of the hypothalamic-pituitary axis (pituitary tumors, head trauma, prior radiation) [4].

Monitoring Schedule

A reasonable monitoring protocol for Louisiana providers managing tesamorelin therapy includes:

• IGF-1 at baseline, 3 months, and every 6 months thereafter
• Fasting glucose or HbA1c at baseline and every 3 months
• Clinical assessment of edema and joint symptoms at each visit
• Annual review of indication and therapeutic benefit, with documented rationale for continuation

The American Association of Clinical Endocrinologists (AACE) recommends that any GH-axis therapy be accompanied by "periodic reassessment of therapeutic goals and documented clinical response" in its growth hormone deficiency guidelines [15].

Drug Interactions

No significant pharmacokinetic drug interactions have been identified for tesamorelin in the FDA label. CYP450-metabolized drugs do not appear to be affected. Tesamorelin may blunt the effect of corticosteroids on GH axis suppression, a consideration for patients on chronic prednisone or dexamethasone [4].

Tesamorelin vs. Other GH Secretagogues: Legal Distinctions in Louisiana

Patients and providers sometimes ask how tesamorelin compares legally with other growth-hormone-releasing peptides such as sermorelin, ipamorelin, or CJC-1295.

Sermorelin held an NDA (NDA 019764) but was voluntarily withdrawn from the market in 2008. It has since been available only as a compounded product. The FDA placed sermorelin on the 503A Category 1 bulks list in 2020, explicitly allowing 503A compounding [16].

Ipamorelin and CJC-1295 have no FDA approval and no NDA. The FDA placed both on the list of bulk drug substances that may not be used in compounding under 503A and 503B (the "Category 2 not-approved" list) in 2024 guidance, meaning compounding pharmacies in Louisiana may not legally compound ipamorelin or CJC-1295 for patient use [17].

Tesamorelin sits in a distinct position: it has an active NDA, is not on the prohibited compounding list, and is not on the explicitly approved compounding list. That regulatory middle ground means 503A compounding is defensible with proper documentation but carries more regulatory uncertainty than sermorelin compounding does.

Telehealth Prescribing of Tesamorelin in Louisiana

Louisiana's telehealth statute (La. R.S. 40:1223.3) and the Louisiana Board of Medical Examiners' telehealth rules permit a provider to prescribe legend drugs following a synchronous audio-video encounter, provided a valid provider-patient relationship is established during that visit. No in-person visit is required for the initial prescription of non-controlled drugs such as tesamorelin [12].

The Drug Enforcement Administration's temporary rules that expanded telemedicine prescribing of controlled substances during the COVID-19 public health emergency do not apply to tesamorelin, because it is not a controlled substance. Louisiana providers can prescribe it via telehealth under state law without any additional federal waiver.

Patients using telehealth platforms should confirm the following before proceeding:

• The prescribing provider holds an active Louisiana medical license
• The platform conducts a synchronous (live video) visit, not asynchronous questionnaire-only intake
• Lab work is ordered and reviewed before dispensing begins
• Prescriptions are sent to a licensed Louisiana or out-of-state (NABP-accredited) pharmacy